[1]
|
Garg, V., Verma, S. and Connelly, K. (2019) Mechanistic Insights Regarding the Role of SGLT2 Inhibitors and GLP1 Agonist Drugs on Cardiovascular Disease in Diabetes. Progress in Cardiovascular Diseases, 62, 349-357.
https://doi.org/10.1016/j.pcad.2019.07.005
|
[2]
|
中国老年2型糖尿病防治临床指南(2022年版) [J]. 中国糖尿病杂志, 2022, 30(1): 2-51.
|
[3]
|
Collaboration, T.E.R.F. (2010) Diabetes Mellitus, Fasting Blood Glucose Concentration, and Risk of Vascular Disease: A Collaborative Meta-Analysis of 102 Prospective Studies. The Lancet, 375, 9733.
https://doi.org/10.1016/S0140-6736(10)60484-9
|
[4]
|
Jia, G., Hill, M.A. and Sowers, J.R. (2018) Diabetic Cardi-omyopathy: An Update of Mechanisms Contributing to This Clinical Entity. Circulation Research, 122, 624-638. https://doi.org/10.1161/CIRCRESAHA.117.311586
|
[5]
|
Cheng, A.Y.Y. (2021) Why Choose between SGLT2 In-hibitors and GLP1-RA When You Can Use Both? The Time to Act Is Now. Circulation, 143, 780-782. https://doi.org/10.1161/CIRCULATIONAHA.120.053058
|
[6]
|
Merovci, A., Solis-Herrera, C., Daniele, G., et al. (2014) Dapagliflozin Improves Muscle Insulin Sensitivity but Enhances Endogenous Glucose Production [Published Correction Appears in J Clin Invest. 2014 May 1, 124(5): 2287]. Jour- nal of Clinical Investigation, 124, 509-514. https://doi.org/10.1172/JCI70704
|
[7]
|
Merovci, A., Mari, A., Solis-Herrera, C., et al. (2015) Dapagliflozin Lowers Plasma Glucose Concentration and Improves β-Cell Function [Published Correction Appears in J Clin Endocrinol Metab. 2017 Dec 1, 102(12): 4662]. The Journal of Clinical Endocrinology & Metabolism, 100, 1927-1932. https://doi.org/10.1210/jc.2014-3472
|
[8]
|
DeFronzo, R.A. (2017) Combination Therapy with GLP-1 Receptor Agonist and SGLT2 Inhibitor. Diabetes, Obesity and Metabolism, 19, 1353-1362. https://doi.org/10.1111/dom.12982
|
[9]
|
Hallow, K.M., Helmlinger, G., Greasley, P.J., et al. (2018) Why Do SGLT2 Inhibitors Reduce Heart Failure Hospitalization? A Differential Volume Regulation Hypothesis. Diabetes, Obe-sity and Metabolism, 20, 479-487.
https://doi.org/10.1111/dom.13126
|
[10]
|
Kario, K., Okada, K., Kato, M., et al. (2018) 24-Hour Blood Pres-sure-Lowering Effect of an SGLT-2 Inhibitor in Patients with Diabetes and Uncontrolled Nocturnal Hypertension: Re-sults from the Randomized, Placebo-Controlled SACRA Study [Published Online Ahead of Print, 2018 Nov 29]. Circu-lation, 139, 2089-2097.
https://doi.org/10.1161/CIRCULATIONAHA.118.037076
|
[11]
|
Wiviott, S.D., Raz, I., Bonaca, M.P., et al. (2019) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 380, 347-357. https://doi.org/10.1056/NEJMoa1812389
|
[12]
|
Scheen, A.J. (2019) Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Current Cardiology Reports, 21, 70. https://doi.org/10.1007/s11886-019-1165-1
|
[13]
|
Horie, I., Abiru, N., Hongo, R., et al. (2018) Increased Sugar In-take as a Form of Compensatory Hyperphagia in Patients with Type 2 Diabetes under Dapagliflozin Treatment. Diabetes Research and Clinical Practice, 135, 178-184.
https://doi.org/10.1016/j.diabres.2017.11.016
|
[14]
|
Miyachi, Y., Tsuchiya, K., Shiba, K., et al. (2018) A Reduced M1-Like/M2-Like Ratio of Macrophages in Healthy Adipose Tissue Expansion during SGLT2 Inhibition. Scientific Re-ports, 8, Article No. 16113.
https://doi.org/10.1038/s41598-018-34305-x
|
[15]
|
Kang, S., Verma, S., Hassanabad, A.F., et al. (2020) Direct Ef-fects of Empagliflozin on Extracellular Matrix Remodelling in Human Cardiac Myofibroblasts: Novel Translational Clues to Explain EMPA-REG Outcome Results. Canadian Journal of Cardiology, 36, 543-553. https://doi.org/10.1016/j.cjca.2019.08.033
|
[16]
|
Kappel, B.A., Lehrke, M., Schütt, K., et al. (2017) Effect of Em-pagliflozin on the Metabolic Signature of Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease. Circulation, 136, 969-972.
https://doi.org/10.1161/CIRCULATIONAHA.117.029166
|
[17]
|
Esterline, R.L., Vaag, A., Oscarsson, J. and Vora, J. (2018) Mechanisms in Endocrinology: SGLT2 Inhibitors: Clinical Benefits by Restoration of Normal Diurnal Metabo-lism? European Journal of Endocrinology, 178, R113-R125.
https://doi.org/10.1530/EJE-17-0832
|
[18]
|
Ling, H., Gray, C.B., Zambon, A.C., et al. (2013) Ca2+/Calmodulin-Dependent Protein Kinase II δ Mediates Myocardial Ischemia/Reperfusion Injury through Nuclear Factor-κB. Circulation Research, 112, 935-944.
https://doi.org/10.1161/CIRCRESAHA.112.276915
|
[19]
|
Andreadou, I., Bell, R.M., Bøtker, H.E. and Zuurbier, C.J. (2020) SGLT2 Inhibitors Reduce Infarct Size in Reperfused Ischemic Heart and Improve Cardiac Function during Ischemic Episodes in Preclinical Models. Biochimica et Biophysica Acta—Molecular Basis of Disease, 1866, Article ID: 165770. https://doi.org/10.1016/j.bbadis.2020.165770
|
[20]
|
Bonnet, F. and Scheen, A.J. (2018) Effects of SGLT2 Inhibitors on Systemic and Tissue Low-Grade Inflammation: The Potential Contribution to Diabetes Complications and Cardiovascular Disease. Diabetes & Metabolism, 44, 457-464.
https://doi.org/10.1016/j.diabet.2018.09.005
|
[21]
|
Sano, M., Goto, S. (2019) Possible Mechanism of Hematocrit Elevation by Sodium Glucose Cotrans39orter 2 Inhibitors and Associated Beneficial Renal and Cardiovascular Effects. Circulation, 139, 1985-1987.
https://doi.org/10.1161/CIRCULATIONAHA.118.038881
|
[22]
|
Januzzi, J.L., Butler, J., Jarolim, P., et al. (2017) Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults with Type 2 Diabetes. Journal of the American College of Cardiology, 70, 704-712.
https://doi.org/10.1016/j.jacc.2017.06.016
|
[23]
|
Lopaschuk, G.D. and Verma, S. (2020) Mechanisms of Cardio-vascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review. JACC: Basic to Translational Science, 5, 632-644.
https://doi.org/10.1016/j.jacbts.2020.02.004
|
[24]
|
Zinman, B., Wanner, C., Lachin, J.M., et al. (2015) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. The New England Journal of Medicine, 373, 2117-2128. https://doi.org/10.1056/NEJMoa1504720
|
[25]
|
Neal, B., Perkovic, V., Mahaffey, K.W., et al. (2017) Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine, 377, 644-657. https://doi.org/10.1056/NEJMoa1611925
|
[26]
|
McMurray, J.J.V., Solomon, S.D., Inzucchi, S.E., et al. (2019) Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. The New England Journal of Medicine, 381, 1995-2008.
|
[27]
|
Cosentino, F., Cannon, C.P., Cherney, D.Z.I., et al. (2020) Efficacy of Ertugliflozin on Heart Fail-ure-Related Events in Patients with Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease: Results of the VERTIS CV Trial. Circulation, 142, 2205-2215. https://doi.org/10.1161/CIRCULATIONAHA.120.050255
|
[28]
|
(2019) Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine, 380, 2295-2306. https://doi.org/10.1056/NEJMoa1811744
|
[29]
|
Nauck, M.A., Quast, D.R., Wefers, J. and Pfeiffer, A.F.H. (2021) The Evolving Story of Incretins (GIP and GLP-1) in Metabolic and Cardiovascular Disease: A Pathophysiological Up-date. Diabetes, Obesity and Metabolism, 23, 5-29.
https://doi.org/10.1111/dom.14496
|
[30]
|
Robinson, L.E., Holt, T.A., Rees, K., et al. (2013) Effects of Exenatide and Liraglutide on Heart Rate, Blood Pressure and Body Weight: Systematic Review and Meta-Analysis. BMJ Open, 3, e001986.
https://doi.org/10.1136/bmjopen-2012-001986
|
[31]
|
Lorenz, M., Lawson, F., Owens, D., et al. (2017) Differential Effects of Glucagon-Like Peptide-1 Receptor Agonists on Heart Rate. Cardiovascular Diabetology, 16, 6. https://doi.org/10.1186/s12933-016-0490-6
|
[32]
|
Nakatani, Y., Kawabe, A., Matsumura, M., et al. (2016) Effects of GLP-1 Receptor Agonists on Heart Rate and the Autonomic Nervous System Using Holter Electrocardiography and Power Spectrum Analysis of Heart Rate Variability. Diabetes Care, 39, e22-e23. https://doi.org/10.2337/dc15-1437
|
[33]
|
Pfeffer, M.A., Claggett, B., Diaz, R., et al. (2015) Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. The New England Journal of Medicine, 373, 2247-2257. https://doi.org/10.1056/NEJMoa1509225
|
[34]
|
Marso, S.P., Daniels, G.H., Brown-Frandsen, K., et al. (2016) Li-raglutide and Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 375, 311-322. https://doi.org/10.1056/NEJMoa1603827
|
[35]
|
Holman, R.R., Bethel, M.A., Mentz, R.J., et al. (2017) Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. The New England Journal of Medicine, 377, 1228-1239. https://doi.org/10.1056/NEJMoa1612917
|
[36]
|
Marso, S.P., Bain, S.C., Consoli, A., et al. (2016) Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 375, 1834-1844. https://doi.org/10.1056/NEJMoa1607141
|
[37]
|
Hernandez, A.F., Green, J.B., Janmohamed, S., et al. (2018) Albiglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease (Harmony Outcomes): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 392, 1519-1529.
|
[38]
|
Gerstein, H.C., Colhoun, H.M., Dagenais, G.R., et al. (2019) Dulaglutide and Cardiovascular Outcomes in Type 2 Diabetes (REWIND): A Double-Blind, Randomised Placebo-Controlled Trial. The Lancet, 394, 121-130.
|
[39]
|
Husain, M., Birkenfeld, A.L., Donsmark, M., et al. (2019) Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. The New England Journal of Medicine, 381, 841-851. https://doi.org/10.1056/NEJMoa1901118
|
[40]
|
Frías, J.P., Guja, C., Hardy, E., et al. (2016) Exenatide Once Weekly plus Dapagliflozin Once Daily versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy (DURATION-8): A 28 Week, Multicentre, Double-Blind, Phase 3, Randomised Controlled Trial [Published Correction Appears in Lancet Diabetes Endocrinol. 2017 Dec, 5(12 ): e8]. The Lancet Diabetes & Endocrinology, 4, 1004-1016.
https://doi.org/10.1016/S2213-8587(16)30267-4
|
[41]
|
Jabbour, S.A., Frías, J.P., Hardy, E., et al. (2018) Safety and Efficacy of Exenatide Once Weekly plus Dapagliflozin Once Daily versus Exenatide or Dapagliflozin Alone in Patients with Type 2 Diabetes Inadequately Controlled with Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. Diabetes Care, 41, 2136-2146. https://doi.org/10.2337/dc18-0680
|
[42]
|
Ludvik, B., Frías, J.P., Tinahones, F.J., et al. (2018) Dulaglutide as Add-On Therapy to SGLT2 Inhibitors in Patients with Inade-quately Controlled Type 2 Diabetes (AWARD-10): A 24-Week, Randomised, Double-Blind, Placebo-Con- trolled Trial [Published Correction Appears in The Lancet Diabetes & Endocrinology 2018 Jun, 6(6): e5]. The Lancet Diabetes & Endocrinology, 6, 370-381. https://doi.org/10.1016/S2213-8587(18)30023-8
|
[43]
|
Dave, C.V., Kim, S.C., Goldfine, A.B., et al. (2021) Risk of Cardiovascular Outcomes in Patients with Type 2 Diabetes after Addition of SGLT2 Inhibi-tors versus Sulfonylureas to Baseline GLP-1RA Therapy [Published Correction Appears in Circulation. 2021 Feb 23, 143(8): e744]. Circulation, 143, 770-779.
https://doi.org/10.1161/CIRCULATIONAHA.120.047965
|
[44]
|
Cosentino, F., Grant, P.J., Aboyans, V., et al. (2020) 2019 ESC Guidelines on Diabetes, Pre-Diabetes, and Cardiovascular Diseases Developed in Collaboration with the EASD [Published Correction Appears in Eur Heart J. 2020 Dec 1, 41(45): 4317]. European Heart Journal, 41, 255-323. https://doi.org/10.1093/eurheartj/ehz828
|
[45]
|
American Diabetes Association (2021) 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care, 44, S111-S124. https://doi.org/10.2337/dc21-S009
|